Date |
Event |
Presentation |
Speakers |
September 27, 2010
|
25th Annual Critical Issues in Tumor Microenvironment, Angiogenesis and Metastasis: from Bench to Bedside to Biomarkers
|
Therapy of Cancer Metastasis: Attacking the Stroma
|
Isaiah J. Fidler
|
|
|
The Biology of Cancer Metastasis
|
Isaiah J. Fidler
|
July 11, 2010
|
Translational Cancer Medicine 2010 (USA)
|
Toward personalized therapy for advanced non-small cell lung cancer: The M. D. Anderson BATTLE Programs
|
Roy S. Herbst
|
May 19, 2010
|
Engineering Antibodies
|
A Computational-Experimental Strategy for the Isolation of Antigen-Specific Antibodies from Immunized Animals
|
George Georgiou
|
|
|
Chairperson’s Opening Remarks
|
George Georgiou
|
|
|
In vitro screening or immunization? Isolating biologically active antibodies
|
George Georgiou
|
January 22, 2010
|
2010 Gastrointestinal Cancers Symposium
|
Surgical Oncologist
|
Roderich Schwarz
|
|
|
Is There Resistance to Anti-angiogenic Agents?
|
Lee M Ellis
|
|
|
GI Cancer Stem Cells: Bench to Bedside
|
Jaffer A. Ajani
|
|
|
Medical Oncologist
|
Gauri Varadhachary
|
|
|
Chemoprevention: Who Can Benefit?
|
Robert S Bresalier
|
|
|
Primer in Cancer Genetics
|
Miguel Rodriguez-Bigas
|
|
|
General Session IX: Cancers of the Colon and Rectum: Multidisciplinary Treatment
|
Cathy Eng
|
|
|
Angiogenesis Inhibition and Its Impact on Future Adjuvant Studies and Advanced Disease
|
Lee M Ellis
|
|
|
Medical Oncologists
|
Cathy Eng
|
September 24, 2009
|
Track 3:Advancing Cancer Therapy : Inaugural Circulating Tumor Cells
|
The Clinical Utility of Circulating Tumor Cell Analysis: What Have We Learned So Far?
|
Beverly C. Handy
|
August 21, 2009
|
Eighth International Congress on Targeted Therapies in Cancer
|
Terminating the Cancer Cell (Cycle)
|
Anas Younes
|
|
|
BiTes
|
Anas Younes
|
June 9, 2009
|
Cell and Tissue-Based Assays for HTS
|
A Novel Platform for High-Throughput Gene Expression Profiling
|
Andreas Jeromin
|
June 8, 2009
|
RNAi for Functional Screens
|
Towards Functional Annotation of the Cancer Genome
|
Michael A. White
|
May 11, 2009
|
Patient Recruitment in Clinical Trials
|
Interactive Open-Forum Format
|
Melynda Geurts, Susan Campbell
|
|
|
Table #7: When Should a Risk Share Model Be Utilized?
|
Melynda Geurts
|
February 17, 2009
|
Pharma/Biotech Patent Litigation
|
Reviewing Recent US Judicial Decisions
|
Thomas J. Kowalski
|
January 26, 2009
|
Biomarker Assay Development
|
Circulating Tumor Cell Assays: A Prognostic and Predictive Factor For Breast, Prostate And Colon Cancer
|
Herbert A Fritsche
|
January 26, 2009
|
Translational Cancer Medicine
|
Circulating Tumor Cell Assays: A Prognostic and Predictive Factor For Breast, Prostate And Colon Cancer
|
Herbert A Fritsche
|
December 4, 2008
|
BIT Life Sciences 2nd Annual World Congress of Gene-2008 (WCG 2008)
|
Application of New Proteomics Technologies to Drug Discovery : Track 1-3
|
Yingming Zhao
|
|
|
Title: TBD:Track 2-2
|
Dihua Yu
|
|
|
Feedstock and Enzyme Improvement for Bioenergy : Track 5-1
|
Joshua S. Yuan
|
November 17, 2008
|
Mastering Process Chemistry
|
Control Strategy in a Quality by Design (QbD) Environment
|
Stephen Liebowitz
|
November 17, 2008
|
BIO-Europe 2008
|
Critical Issues to Consider when Entering the U.S. Market and Partnering with U.S. Companies
|
Steve Bryant
|
November 5, 2008
|
DIA's 6th Canadian Annual Meeting: Benefit and Risk Management: An Evolution in Progress
|
TRACK 1 : USE OF IMAGING TO DETERMINE EFFICACY
|
Gordon Mills
|
October 12, 2008
|
15th North American Regional Meeting - International Society for the Study of Xenobiotics
|
Crystallographic Studies of CYP46A1
|
Irina A. Pikuleva
|
September 29, 2008
|
Biomarker Data Analysis
|
Chairperson’s Opening Remarks
|
George A. Calin
|
|
|
High-Throughput Functional Proteomics Facilitates a Systems Biology Approach to Personalized Medicine
|
Gordon Mills
|
|
|
Semantic Web Abstractions for Biomedical Informatics: A Better Foundation for Integrating Sensitive Heterogeneous Data Sources
|
Jonas S. Almeida
|
July 20, 2008
|
WORLD SUMMIT OF ANTIVIRALS Combating Severe Viral Infections
|
Session 2: Etiology and Epidemiology of Viral Infections
|
R. Palmer Beasley
|
|
|
Session 3: Epidemiology and Virology
|
Lu-Yu Hwang
|
|
|
Epidemiology and Prevention of HIV, HBV and HCV Infection among Hard to Reach Drug Users: Experiences from the Inner City Neighborhoods of the United States
|
Lu-Yu Hwang
|
July 19, 2008
|
22nd Annual Symposium of The Protein Society
|
Concurrent Morning Symposia 11: Allosteric Control and Conformational Changes
|
Vincent Hilser
|
May 30, 2008
|
ASCO Annual'08 Meeting
|
breast cancer-- Postmenopausal Hormone Therapy: Friend or Foe? (M19)
|
Peter Ravdin
|
|
|
cancer genetics-- Single Nucleotide Polymorphisms, Clinical Trials, and Tobacco Research: Search for the Smoking Gun
|
Margaret R. Spitz
|
|
|
cancer prevention/epidemiology-- Single Nucleotide Polymorphisms, Clinical Trials, and Tobacco Research: Search for the Smoking Gun
|
Margaret R. Spitz
|
|
|
cancer prevention/epidemiology-- Postmenopausal Hormone Therapy: Friend or Foe? (M19)
|
Peter Ravdin
|
|
|
developmental therapeutics-- c-MET Inhibition for Cancer Treatment
|
Razelle Kurzrock
|
|
|
developmental therapeutics-- Issues in the Modulation of Angiogenesis Pathways (M10)
|
Roy S. Herbst
|
|
|
developmental therapeutics-- Picking the Winners Through Biomarker Enrichment: Could This Be the End of Phase III Trials?
|
Chris H. Takimoto
|
|
|
gastrointestinal (colorectal) cancer-- Advances in Anal Cancer Management (M01)
|
Cathy Eng
|
|
|
gastrointestinal (colorectal) cancer-- Intraperitoneal Treatment for Gastrointestinal Cancer: Role of Debulking and Chemotherapy
|
Cathy Eng
|
|
|
gastrointestinal (noncolorectal) cancer-- Management of Neuroendocrine Cancers: Radiopharmaceuticals, Novel Therapies, and the Impact of Octreotide (CPO07A)
|
James C. Yao
|
|
|
gastrointestinal (noncolorectal) cancer-- Management of Neuroendocrine Cancers: Radiopharmaceuticals, Novel Therapies, and the Impact of Octreotide (CPO07B)
|
James C. Yao
|
|
|
gastrointestinal (noncolorectal) cancer-- Intraperitoneal Treatment for Gastrointestinal Cancer: Role of Debulking and Chemotherapy
|
Cathy Eng
|
|
|
gastrointestinal (noncolorectal) cancer Picking the Winners Through Biomarker Enrichment: Could This Be the End of Phase III Trials?
|
Chris H. Takimoto
|
|
|
genitourinary cancer-- What to Do for the Prostate Cancer Patient with a Rising Prostate-Specific Antigen and No Disease on Imaging Studies CPO20A)
|
Paul Mathew
|
|
|
genitourinary cancer What to Do for the Prostate Cancer Patient with a Rising Prostate-Specific Antigen and No Disease on Imaging Studies (CPO20B)
|
Paul Mathew
|
|
|
gynecologic cancer-- Practical Aspects of Intraperitoneal Chemotherapy Administration (M20)
|
Maurie Markman
|
|
|
lung cancer-- Therapeutic Modalities for “Small” Stage I Lung Cancers
|
Robert Timmerman
|
|
|
lymphoma and plasma cell disorders-- The Role of Maintenance Therapy in Follicular Lymphoma: Pros and Cons
|
Peter McLaughlin
|
|
|
patient and survivor care-- Practical Aspects of Intraperitoneal Chemotherapy Administration (M20)
|
Maurie Markman
|
|
|
patient and survivor care-- Picking the Winners Through Biomarker Enrichment: Could This Be the End of Phase III Trials?
|
Chris H. Takimoto
|
|
|
sarcoma/bone and soft tissue cancers-- Management of Soft Tissue Sarcoma for the Community Oncologist (M12)
|
Shreyaskumar Patel
|
|
|
tumor biology-- Management of Soft Tissue Sarcoma for the Community Oncologist (M12)
|
Shreyaskumar Patel
|
|
|
meet the professor sessions-- Advances in Anal Cancer Management (M01)
|
Cathy Eng
|
|
|
meet the professor sessions-- Issues in the Modulation of Angiogenesis Pathways (M10)
|
Roy S. Herbst
|
|
|
meet the professor sessions-- Practical Aspects of Intraperitoneal Chemotherapy Administration (M20)
|
Maurie Markman
|
|
|
meet the professor sessions-- Postmenopausal Hormone Therapy: Friend or Foe? (M19)
|
Peter Ravdin
|
|
|
meet the professor sessions-- Management of Soft Tissue Sarcoma for the Community Oncologist (M12)
|
Shreyaskumar Patel
|
|
|
clinical problems in oncology-- Management of Neuroendocrine Cancers: Radiopharmaceuticals, Novel Therapies, and the Impact of Octreotide (CPO07A)
|
James C. Yao
|
|
|
clinical problems in oncology-- Management of Neuroendocrine Cancers: Radiopharmaceuticals, Novel Therapies, and the Impact of Octreotide (CPO07B)
|
James C. Yao
|
|
|
clinical problems in oncology-- What to Do for the Prostate Cancer Patient with a Rising Prostate-Specific Antigen and No Disease on Imaging Studies (CPO20A)
|
Paul Mathew
|
|
|
clinical problems in oncology-- What to Do for the Prostate Cancer Patient with a Rising Prostate-Specific Antigen and No Disease on Imaging Studies (CPO20B)
|
Paul Mathew
|
March 30, 2008
|
Metabolic Pathways of Longevity
|
The Role of Nutrient Sensing in Aging II: Caloric Restriction
|
Arlan G Richardson
|
|
|
Oxidative Stress, Aging, & Insulin/IGF1 Signaling
|
Arlan G Richardson
|
March 30, 2008
|
Nuclear Receptors: Steroid Sisters
|
Differentiation and Development
|
David J. Mangelsdorf
|
|
|
Steroid Receptor Signaling and Dynamics
|
Stephen R. Hammes
|
|
|
Steroid Receptors and Cancer
|
Rakesh Kumar
|
|
|
Workshop 3 - Hot Topics: Chromatin/Transcription
|
Raj Kumar
|
March 30, 2008
|
Nuclear Receptors: Orphan Brothers
|
Differentiation and Development
|
David J. Mangelsdorf
|
|
|
Steroid Receptor Signaling and Dynamics
|
Stephen R. Hammes
|
|
|
Steroid Receptors and Cancer
|
Rakesh Kumar
|
|
|
Workshop 3 - Hot Topics: Chromatin/Transcription
|
Raj Kumar
|
February 17, 2008
|
GRC - Peptides, Chemistry & Biology Of
|
Monitoring and Manipulating the Proteome With Peptoids
|
Thomas Kodadek
|
December 1, 2007
|
47TH American Socieity of Cell Biology
|
Cell Matrix Interactions (Room 140A)
|
Muhammad H. Zaman
|
|
|
Cellular Biology of Gap Junction Channels (Room 103A)
|
Guillermo Altenberg, Srikanth Polusani
|
|
|
Translocon-mediated Head-First Insertion and Rotation of a Signal Anchor during Cotranslational Integration.
|
A E Johnson
|
|
|
Mechanism of the Neurospora Circadian Negative Feedback Loop.
|
Yi Liu
|
November 7, 2007
|
Srial II: Advances and Challenges Toward Major Diseases: Extension on New Hope Nov (07-13)
|
Session 2: Anti-Cancer/Tumors Drug Discovery & Development and Current Status of the Innovative Therapeutics (Part I) (13:30-17:30)
|
Dr. Xiaodong Cheng
|
|
|
session 2: Identification of Selective Anti-pancreatic Cancer Inhibitors Using Synthetic Lethal Chemical Screening (14:30-14:50)
|
Dr. Xiaodong Cheng
|
|
|
Session 11: Anti-Infectious Drug Discovery & Development (II) (09:00-12:20)
|
Stanley J. Watowich
|
|
|
Session 11: Global Grid-computing Initiative to Discover Novel Dengue and Hepatitis C Antivirals (09:40-10:00)
|
Stanley J. Watowich
|
October 17, 2007
|
Inaugral Nuclear Harmone Receptors Modulators: Targets for Drug Discovery Oct (17-18)
|
NUCLEAR HORMONE RECEPTORS (14:10-18:50)
|
Carole R. Mendelson
|
|
|
NUCLEAR HORMONE RECEPTORS: Progesterone Receptor Modulation of Inflammatory Signaling in Pregnancy and Labor (17:20-17:50)
|
Carole R. Mendelson
|